bpc-157 dosage for tendon injury Dosing (Common Protocols), 🔹 Oral / Subcutaneous, • 500 mcg daily, • Duration: 6 weeks, 🔹 Intramuscular / Peritendinous, • 1 mg daily, • Duration: 6 weeks, ⚠️ Note:, Not approved by FDA or BPC-157 Dosage: A Complete Guide

Digestive disorders including Celiac disease, atrophic gastritis, and shortened small intestines can all increase the risk of vitamin B12 deficiency since nutrients arent as easily absorbed

In fact its a time bomb and there will be guaranteed casualties amongst B12 deficient patients who only take oral tablets during this period

The risks that should be considered when evaluating BPC-157 benefits are listed below

The Nature Scientific Reports 2016 study confirmed that GHK-Cu produced no cytotoxicity to human keratinocytes at concentrations up to 5,800 micromolar over 72 hours and did not induce inflammatory biomarkers